Evidence map›Paper›PMID 34989105›Full record

ArticleEuropean journal of heart failure2022

Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.

Finnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, Milton Packer, Michele Senni, Mauro Gori, Pardeep S Jhund, Martina M McGrath, Jean L Rouleau, Victor Shi and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Observational
  7. Review
  8. Review
  9. Article
  10. Review
  11. 2024 update in heart failure.ESC heart failure · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Updates in Cardiorenal Syndrome.The Medical clinics of North America · 2023
    Review
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 6 countries.

Finnian R Mc CauslandRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Martin P LefkowitzNovartis Pharmaceuticals, East Hanover, NJ, USA.
Brian ClaggettHarvard Medical School, Boston, MA, USA.
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
Michele SenniCardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
Mauro GoriCardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
Pardeep S JhundBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Martina M McGrathRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Jean L RouleauInstitut de Cardiologie de Montréal, Université de Montréal, Montreal, Canada.
Victor ShiNovartis Pharmaceuticals, East Hanover, NJ, USA.
Karl SwedbergDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Muthiah VaduganathanHarvard Medical School, Boston, MA, USA.
Faiez ZannadUniversité de Lorraine, Inserm CIC1433, CHRU de Nancy, Nancy, France.
Marc A PfefferHarvard Medical School, Boston, MA, USA.
Michael ZileMedical University of South Carolina, Charleston, SC, USA.
John J V McMurrayCardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy.
Scott D SolomonHarvard Medical School, Boston, MA, USA.
Harvard University · USOspedale Papa Giovanni XXIII · ITBaylor University Medical Center · USBrigham and Women's Hospital · USInserm · FRNovartis (United States) · USRalph H. Johnson VA Medical Center · USTris Pharma (United States) · USUniversité de Montréal · CAUniversity of Glasgow · GBUniversity of Gothenburg · SE

Funding

Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRDU01DK096189 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2013 to 2017
$2.4M
Cardiac Complications of Hemodynamic Instability during HemodialysisK23DK102511 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2015 to 2019
$964k
Patient Symptoms on Hemodialysis-Timing, Variability and CausesR03DK122240 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2019 to 2020
$179k
NIDDK NIH HHS K23 DK102511NIDDK NIH HHS R03 DK122240NIDDK NIH HHS U01 DK096189
6 · The paper itself

Abstract

aimsPatients with heart failure are at higher risk of progression to end-stage renal disease (ESRD), regardless of ejection fraction (EF). We assessed the renal effects of angiotensin-neprilysin inhibition in a pooled analysis of 13 195 patients with heart failure with reduced and preserved EF. METHODS AND

resultsWe combined data from PARADIGM-HF (EF ≤40%; n = 8399) and PARAGON-HF (EF ≥45%; n = 4796) in a pre-specified pooled analysis. We assessed the effect of treatment (sacubitril/valsartan vs. enalapril or valsartan) on a composite of either ≥50% reduction in estimated glomerular filtration rate (eGFR), ESRD, or death from renal causes, in addition to changes in eGFR slope. We assessed whether baseline renal function or EF modified the effect of therapy on renal outcomes. At randomization, eGFR was 68 ± 20 ml/min/1.73 m

conclusionsIn patients with heart failure, sacubitril/valsartan reduced the risk of serious adverse renal outcomes and slowed decline in eGFR, compared with valsartan or enalapril, independent of baseline renal function.

Indexed as

Heart FailureKidney Failure, ChronicAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsBiphenyl CompoundsDrug CombinationsEnalaprilHumansKidneyNeprilysinStroke VolumeTetrazolesValsartanAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsBiphenyl CompoundsDrug CombinationsEnalaprilNeprilysinsacubitrilTetrazolesValsartanChronic kidney diseaseHeart failureRenal outcomes

Identifiers

PMID34989105
PMCPMC9253196
OpenAlexW4205589289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.